HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Percutaneous coronary angioplasty in diabetic patients: new prospects with drug-eluting stents].

Abstract
Coronary revascularization procedures are associated with less favourable outcomes in diabetic patients as compared to non-diabetic individuals. Especially, percutaneous coronary angioplasty (PTCA) is associated with a high level of restenosis and recurrent cardiac morbidity and mortality. In diabetic patients, PTCA should ideally be combined with stents. Bare-metal stents reduce by almost half the risk of restenosis, but this favourable effect decreases with the vessel calibre, a common finding in diabetic patients. Drug-eluting stents containing pharmacological agents that can reduce the risk of restenosis (sirolimus, paclitaxel) provide better angiographic results, including in small coronary arteries, and this effect has been shown to be accompanied by significant reduction of both morbidity and mortality. Such preliminary results obtained in the general population (including around 20% of diabetic subjects) deserve further confirmation in a large clinical trial specifically devoted to diabetic patients. Drug-eluting stents may represent a major advance in the management of diabetic patients with coronary heart disease in the near future.
AuthorsF Warzee, V Legrand, A J Scheen
JournalRevue médicale de Liège (Rev Med Liege) Vol. 59 Issue 12 Pg. 711-6 (Dec 2004) ISSN: 0370-629X [Print] Belgium
Vernacular TitleAngioplastie percutanée coronaire chez le patient diabétique. Partie 3: Nouvelles perspectives apportées par les stents enrobés.
PMID15658058 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Platelet Aggregation Inhibitors
  • Paclitaxel
  • Sirolimus
Topics
  • Angioplasty, Balloon, Coronary (instrumentation)
  • Coronary Disease (therapy)
  • Coronary Restenosis (prevention & control)
  • Diabetes Complications (therapy)
  • Drug Delivery Systems
  • Humans
  • Paclitaxel (therapeutic use)
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Sirolimus (therapeutic use)
  • Stents

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: